Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.
暂无分享,去创建一个
Wei Shi | Sharon Nofech-Mozes | Melania Pintilie | Fei-Fei Liu | T. Nielsen | T. Whelan | D. Voduc | A. Fyles | Fei-Fei Liu | M. Pintilie | D. McCready | L. Weir | I. Olivotto | W. Shi | S. Nofech-Mozes | N. Miller | S. Done | Torsten O Nielsen | Martin C Chang | Timothy J Whelan | Susan J Done | David Voduc | Naomi Miller | David R McCready | Anthony W Fyles | Lorna M Weir | Ivo A Olivotto | Martin C. Chang
[1] F. Cardoso,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Melania Pintilie,et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. , 2004, The New England journal of medicine.
[3] R. Pötter,et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. , 2005, International journal of radiation oncology, biology, physics.
[4] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[5] S. Duffy,et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. , 2013, European journal of cancer.
[6] C. Sotiriou,et al. Luminal breast cancer: from biology to treatment , 2013, Nature Reviews Clinical Oncology.
[7] S. O'toole,et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Bartlett,et al. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. , 2012, American journal of clinical pathology.
[10] M. Castiglione,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Barbara L. Smith,et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Dowsett,et al. International Web-based consultation on priorities for translational breast cancer research , 2007, Breast Cancer Research.
[13] E. Mardis,et al. A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen , 2012, Clinical Cancer Research.
[14] T. Nielsen,et al. Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Lajos Pusztai,et al. Gene expression profiling of breast cancer , 2009, Breast Cancer Research.
[16] Matt van de Rijn,et al. Gene expression profiling of breast cancer. , 2008, Annual review of pathology.
[17] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[18] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[19] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[20] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.
[21] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[22] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[23] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[24] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[25] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[26] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[27] Krystyna Kiel,et al. Breast cancer. Clinical practice guidelines in oncology. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[28] J. Bellon,et al. ACR Appropriateness Criteria® Conservative surgery and Radiation – Stage I and II Breast Carcinoma , 2011, The breast journal.
[29] Barbara L. Smith,et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[31] T. Julian,et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). , 2009, International journal of radiation oncology, biology, physics.
[32] P. Sismondi,et al. Breast-Conservative Surgery With and Without Radiotherapy in Patients Aged 55–75 Years With Early-Stage Breast Cancer: A Prospective, Randomized, Multicenter Trial Analysis After 108 Months of Median Follow-up , 2014, Annals of Surgical Oncology.
[33] S. Giordano. Radiotherapy in older women with low-risk breast cancer: why did practice not change? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.